bluebird bio announced on June 2, 2025, the completion of its sale to funds managed by global investment firms Carlyle and SK Capital Partners, LP. With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer be publicly listed.
Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. David Meek has assumed the role of Chief Executive Officer of bluebird, leading a new management team.
This acquisition marks a new era for bluebird, with a focus on expanding manufacturing capacity, streamlining the patient journey, and strengthening payer partnerships. For Carlyle, this strategic investment expands its healthcare portfolio and demonstrates its commitment to backing companies with groundbreaking therapies to improve patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.